Replies to post #1310 on Vascular Biogenics Ltd (VBLT)

[gr8db8]

Agree that median OS has been reached for both arms - assuming Avastin and VB-111 behave like they did historically and in phase 2, respectively.

[staccani]

Now that we have safety risk out of the way, we can focus only on efficacy.
Based on my calculations of ca 50% of patients enrolled on avg 12 months ago and another 50% enrolled as avg ca 18 months ago, considering that BEV historical has less than 25% survival at 12 months, we should be well positioned to meet the primary endpoint already.

The longer it takes for the 189th event to occur , the higher the VB-111 improvement most likely will be, so the next few months will give us a good opportunity to add shares at least until they announce reaching the 189th event,after which some reasonable estimates about VB 111 medium term survival improvement can be made.